Alkeon Capital Management - MEREO BIOPHARMA GROUP PLC ownership

MEREO BIOPHARMA GROUP PLC's ticker is MREO and the CUSIP is 589492107. A total of 74 filers reported holding MEREO BIOPHARMA GROUP PLC in Q2 2021. The put-call ratio across all filers is 0.68 and the average weighting 0.2%.

Quarter-by-quarter ownership
Alkeon Capital Management ownership history of MEREO BIOPHARMA GROUP PLC
ValueSharesWeighting
Q3 2023$4,822,149
-2.3%
3,738,1000.0%0.01%0.0%
Q2 2023$4,934,292
+192.6%
3,738,100
+56.7%
0.01%
+125.0%
Q1 2023$1,686,381
+5.3%
2,385,600
+11.7%
0.00%
-33.3%
Q4 2022$1,601,700
-12.9%
2,135,6000.0%0.01%0.0%
Q3 2022$1,839,000
-5.4%
2,135,600
+23.0%
0.01%
+20.0%
Q2 2022$1,944,000
-10.3%
1,735,600
-10.3%
0.01%
+25.0%
Q1 2022$2,168,000
-30.0%
1,935,6000.0%0.00%
-33.3%
Q4 2021$3,097,000
-33.9%
1,935,6000.0%0.01%
-25.0%
Q3 2021$4,684,000
-23.7%
1,935,6000.0%0.01%
-11.1%
Q2 2021$6,136,000
-5.9%
1,935,6000.0%0.01%
-10.0%
Q1 2021$6,523,000
-5.9%
1,935,6000.0%0.01%
-9.1%
Q4 2020$6,929,0001,935,6000.01%
Other shareholders
MEREO BIOPHARMA GROUP PLC shareholders Q2 2021
NameSharesValueWeighting ↓
COMMODORE CAPITAL LP 1,972,958$4,775,0001.26%
Altium Capital Management LP 1,250,000$3,025,0000.79%
Rubric Capital Management LP 11,300,000$27,346,0000.76%
Vivo Capital, LLC 6,907,189$16,715,0000.75%
DAFNA Capital Management LLC 1,126,613$2,726,0000.72%
SILVERARC CAPITAL MANAGEMENT, LLC 365,661$885,0000.50%
Orbimed Advisors 17,264,764$41,781,0000.46%
Delphi Management Partners VIII, L.L.C. 256,734$621,0000.45%
Endurant Capital Management LP 746,514$1,807,0000.41%
Affinity Asset Advisors, LLC 650,000$1,573,0000.40%
View complete list of MEREO BIOPHARMA GROUP PLC shareholders